参一胶囊联合GP方案治疗晚期非小细胞肺癌临床观察

目的观察参一胶囊联合GP方案治疗晚期非小细胞肺癌（NSCLC）的临床疗效和患者的耐受性。方法77例晚期非小细胞肺癌患者随机分组，治疗组39例采用参一胶囊加GP方案;对照组38例，仅采用GP方案。结果治疗组近期有效率48.7%，临床获益率82.1%；对照组有效率36.8%，临床获益率63.2%，有效率两组比较差异无统计学意义（P＞0.05），临床获益率两组比较差异有统计学意义(P<0.05)。主要不良反应为骨髓抑制和恶心呕吐，治疗组Ⅲ/Ⅳ度反应明显低于对照组，两组比较差异有统计学意义。结论参一胶囊联合GP方案对晚期非小细胞肺癌具有增加疗效，减轻不良反应，提高患者耐受性的作用，值得临床推广应用。

Clinical Study of GP Regimen Plus Gensing Rg3in Treatment of Advanced Non-small Cell Lung Cancer

Objective To study the clinical effect and toleration of Rg3combination with chemotherapy regimen—GP in patients with advanced non-small cell lung cancer(NSCLC).Methods Seventy-seven patients were divided into two groups randomly.Thirty-nine patients as treatment group,treated by Rg3 plus GP regimen,and thirty-eight patients as the control group,only treated by GP regimen.Results The response rate was 48.7%in treatment group and 36.8%in control,The clinical benefit rate(disease control rate)was 82.1%and 63.2% respectively(P<0.05).Conclusion Rg3combined with GP regimen could increase the therapeutic effects and decrease the side effects of chemotherapy in the patients with advanced non-small cell lung cancer.